Core Insights - Holzer & Holzer, LLC is investigating whether RxSight, Inc. complied with federal securities laws following a decline in financial performance [1] - RxSight announced preliminary financial results for Q2 2025, indicating decreases in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses [1] - The announcement led to a drop in the company's stock price [1] Financial Performance - RxSight revealed declines in revenue and sales of Light Delivery Devices for the second quarter of 2025 [1] - The company also revised its full-year 2025 guidance downward [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in representing shareholders and investors in securities litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Johnson Fistel, PLLP is investigating RxSight, Inc. for potential violations of federal securities laws related to misleading statements and undisclosed material information to investors [1][3]. Company Overview - RxSight, Inc. is facing scrutiny regarding its business outlook and product adoption trends, particularly after reporting significant declines in Light Delivery Device (LDD) sales and total revenue for Q2 2025 [3]. Financial Performance - On July 9, 2025, RxSight released preliminary financial results indicating notable declines in LDD sales and usage of its light adjustable intraocular lenses (LALs) [3]. - The company revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint, attributing this to "adoption challenges over the last few quarters" [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether RxSight misled investors about its financial performance and future prospects [3]. - Investors who purchased RxSight securities and incurred losses may be eligible to participate in the investigation [2]. Whistleblower Information - Individuals with nonpublic information about RxSight are encouraged to assist with the investigation or explore options under the SEC Whistleblower Program, which may offer rewards of up to 30% of any successful enforcement action [4]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with a strong track record in securing recoveries for clients [5][6].

Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Wednesday, while the Dow rose 0.18% to 44,319.31, the NASDAQ increased 0.62% to 20,545.29, and the S&P 500 climbed 0.31% to 6,245.11 [1] - Communication services shares increased by 1.1%, while consumer staples stocks dipped by 1% [1] Commodity News - Oil prices rose by 0.6% to $68.74, while gold prices fell by 0.1% to $3,315.70. Silver decreased by 0.4% to $36.610, and copper dropped by 3.8% to $5.4715 [5] European Market - European shares showed positive performance, with the eurozone's STOXX 600 rising 0.71%, Spain's IBEX 35 Index increasing by 1.07%, London's FTSE 100 gaining 0.13%, Germany's DAX 40 up by 1.32%, and France's CAC 40 rising by 1.40% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei gaining 0.33%, while Hong Kong's Hang Seng fell by 1.06%, China's Shanghai Composite declined by 0.13%, and India's BSE Sensex decreased by 0.21% [7] Company Developments - Calidi Biotherapeutics, Inc. saw its shares surge by 353% to $1.48 due to advancements in cancer treatment [9] - SU Group Holdings Limited's shares increased by 155% to $1.1609 after securing an HK$88.5 million hospital contract [9] - Evoke Pharma, Inc. shares rose by 171% to $7.20 following a notice of allowance for a U.S. patent application [9] - Bitmine Immersion Technologies, Inc. shares dropped by 47% to $59.22 after filing for a mixed shelf [9] - RxSight, Inc. shares fell by 42% to $7.39 after revising its 2025 revenue guidance downwards [9] - Vertical Aerospace Ltd. shares decreased by 31% to $4.77 after announcing a $60 million public offering at $5/share [9] Inventory Data - U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May, aligning with preliminary estimates [11] - U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, marking the largest gain since January [11]

Summary of RxSight Q2 Preannounced Earnings Call Company Overview - **Company**: RxSight (RXST) - **Date of Call**: July 08, 2025 - **Key Speakers**: Ron Kurtz (President and CEO), Shelly Tunin (CFO) Core Industry Insights - **Industry**: Medical Devices, specifically focusing on premium intraocular lenses (IOLs) and related technologies - **Market Dynamics**: The company is experiencing challenges in sales due to slower adoption rates among new customers and increased competition in the premium IOL market Financial Performance - **Q2 2025 Revenue**: $33.6 million, a decrease of 4% year-over-year and 11% sequentially from Q1 2025 [7] - **LDD Sales**: 40 units sold, down 49% year-over-year and 45% sequentially from Q1 2025 [8] - **Installed Base**: 1,084 units, up 34% year-over-year and 4% sequentially [9] - **Revised Full Year 2025 Revenue Guidance**: Reduced from $160 million to a range of $120 million to $130 million, reflecting a decrease of 14% to 7% compared to 2024 [9] - **Gross Margin Guidance**: Revised to 72-74%, an increase from previous guidance of 71-73% [10] - **Operating Expenses**: Expected to be in the range of $145 million to $155 million, representing a year-over-year increase of 7% to 14% [10] Key Challenges and Strategic Responses - **Decline in LDD and LAL Sales**: The company attributes the decline to longer capital equipment acquisition cycles and slower ramp-up in LAL utilization, which began in 2024 [5][7] - **Commercial Strategy Shift**: RxSight is pivoting to enhance clinical support, education, and engagement efforts to improve LAL utilization and drive sales [5][11] - **Customer Support Model**: A data-driven approach will be implemented to analyze utilization trends and provide targeted interventions [11][12] Competitive Landscape - **Market Competition**: Increased competition from new product launches in the multifocal lens space is impacting sales [57][60] - **Impact of Macroeconomic Factors**: The overall cataract market in the U.S. has been flat, affecting premium IOL sales [61] Future Outlook - **Long-term Growth Potential**: RxSight remains optimistic about the long-term benefits of its technology and plans to leverage new international markets, including Korea, Singapore, and the EU [13][33] - **Focus on Customer Success**: The company aims to empower clinical partners to enhance patient outcomes and drive further adoption of LAL technology [11][34] Additional Insights - **Utilization Trends**: LAL utilization was down approximately 21% year-over-year in Q2, with expectations for continued decline in the second half of 2025 [24] - **Customer Feedback**: Existing customers generally report favorable outcomes, but the company is focusing on identifying barriers to adoption among newer accounts [67][68] - **Sales Strategy Adaptation**: The company is refining its approach to better support newer accounts and enhance their adoption of LAL technology [48][87] This summary encapsulates the key points discussed during the RxSight Q2 earnings call, highlighting the company's current challenges, strategic responses, and future outlook in the medical device industry.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (Commission File Number) (IRS Employer Identification No.) 100 Columbia Aliso Viejo, California 92656 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Numbe ...

Core Viewpoint - RxSight, Inc. has announced preliminary financial results for Q2 2025, indicating a decrease in revenue and a revised full-year guidance, while also focusing on enhancing customer success and engagement with clinical partners [1][3]. Preliminary Second Quarter 2025 Results - Preliminary revenue for Q2 2025 is expected to be approximately $33.6 million, a decrease of 4% year-over-year and an 11% decrease compared to Q1 2025 [8]. - The company sold 27,380 Light Adjustable Lenses (LAL®/LAL+®), reflecting a 1% decrease in procedure volume from Q1 2025 but a 13% increase from Q2 2024 [8]. - The sale of 40 Light Delivery Devices (LDD™s) saw a significant decline, with a 45% decrease compared to Q1 2025 and a 49% decrease compared to Q2 2024 [8]. - As of June 30, 2025, the installed base of LDDs increased to 1,084, a 34% growth from 810 LDDs at the end of Q2 2024 [8]. Revised 2025 Guidance - Full-year revenue guidance has been revised downward to a range of $120.0 million to $130.0 million, a decrease from the previous range of $160.0 million to $175.0 million, implying a decrease of 14% to 7% compared to 2024 [9]. - Gross margin guidance has been increased to a range of 72% to 74%, up from the previous range of 71% to 73%, representing an increase of 130 to 330 basis points compared to 2024 [9]. - Operating expense guidance is set between $145.0 million and $155.0 million, indicating an increase of 7% to 14% compared to 2024, which includes non-cash stock-based compensation expenses estimated between $27.0 million and $30.0 million [9].

Core Insights - Investors in the Medical - Instruments sector may consider Fresenius (FMS) or RxSight, Inc. (RXST) as potential undervalued stocks [1] Valuation Metrics - Fresenius has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while RxSight, Inc. has a Zacks Rank of 4 (Sell) [3] - FMS has a forward P/E ratio of 12.19, significantly lower than RXST's forward P/E of 2,025.00, suggesting FMS is more attractively priced [5] - The PEG ratio for FMS is 1.09, while RXST's PEG ratio is 53.43, indicating FMS has a better growth outlook relative to its valuation [5] - FMS has a P/B ratio of 0.97, compared to RXST's P/B of 1.96, further supporting FMS as the more undervalued option [6] - Based on these valuation metrics, FMS holds a Value grade of B, while RXST has a Value grade of F, reinforcing FMS as the superior value option [6]

RxSight LAL Technology & Benefits - The Light Adjustable Lens (LAL) is the only customizable IOL for optimized vision without glasses[11] - LAL eyes have better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl ≤ 050 D)[15] - 92% of surveyed customers believe LAL provides the highest quality of vision[25] - Over 90% of patients achieved 20/25 distance and J2 near vision without glasses in real-world data from over 3,000 eyes[25] - In an RxSight customer survey, 40% of LAL patients would have received a non-premium IOL[26] Market & Financial Performance - Approximately 32 million global cataract procedures are performed annually, including about 5 million in the U.S[9] - The global premium IOL market sees approximately 5 million procedures annually, including about 1 million in the U S[10] - Average additional practice net revenue per LAL implanted is $2,064[27,28] - RxSight's total revenue in Q1 2025 reached $34 million, a 36% growth compared to Q1 2024[30] - The LDD installed base grew by 43% compared to Q1 2024[30] Future Growth & Expansion - US Premium Cataract Surgery is expected to grow from 20% to approximately 35% of overall cataract procedures[32] - Key OUS markets make up >80% of global procedures with growing procedure potential[39]

Group 1 - The focus is on Canadian stocks, particularly in the technology and growth sectors, emphasizing the importance of disruptive companies that can transform their industries [1] - Mid-cap companies with strong management and high growth potential are highlighted as key targets for achieving alpha returns [1] - The strategy includes buying swing positions in quality companies when they revert to their long-term averages, combining technical setups with solid fundamentals to outperform the market [1]

Summary of RxSight (RXST) Conference Call Company Overview - **Company**: RxSight (RXST) - **Event**: 2025 Conference on May 27, 2025 Key Industry Insights - **LAL Volumes**: April showed improvement over March, with late April trends indicating stabilization in macroeconomic conditions, which positively impacted procedural volumes [2][4][6] - **Premium IOL Market**: The premium intraocular lens (IOL) market in the U.S. has been largely flat over the years, with growth primarily driven by LAL, which accounts for 40-45% of its patient base coming from monofocal IOL patients [7][8] - **Market Recovery**: The company anticipates that the macroeconomic headwinds affecting premium IOLs are likely temporary, with expectations of improvement in the second half of the year as equity markets recover [12][18] Financial Performance and Guidance - **Utilization Trends**: The company noted that utilization has been impacted by macroeconomic factors and competition, but they are implementing new programs to enhance same-store sales and utilization [20][21] - **Sales Guidance for 2025**: The company expects LDD (Laser Delivery Device) sales to increase year-over-year, with the second half of 2025 projected to be stronger than the first half, contingent on macroeconomic stability [45][48] Competitive Landscape - **Competition from Alcon**: The introduction of PanOptix Pro by Alcon has created competition in the presbyopia-correcting IOL space, but the company believes significant clinical differences between products are unlikely [15][16] - **Market Share Dynamics**: RxSight has been gaining market share, with estimates suggesting they could reach 11-12% market share, while the overall market has been flat to down [36][37] Operational Strategies - **Utilization Programs**: The company is focusing on leveraging best practices from high-volume centers to improve utilization across their installed base, which is seen as a significant growth lever [21][24] - **Surgeon Training**: There is an ongoing effort to enhance the training of newer surgeon cohorts, as the 2024 class has not yet reached the same utilization levels as previous classes [27][30] Additional Considerations - **Psychological and Political Factors**: The company acknowledges that psychological and political factors will play a role in market recovery and consumer confidence, which are critical for achieving higher sales guidance [12][48] - **Long-term Growth Drivers**: The trend towards quality of vision over quantity is expected to continue driving growth in the premium IOL market, particularly with the LAL [12][24] This summary encapsulates the key points discussed during the conference call, highlighting the company's outlook, market dynamics, and strategic initiatives.